IDH1 and acute myeloid leukemia: As highlighted here, a series of studies have rapidly suggested that mutations in TET2, IDH1/2, and DNMT3a will likely refine our current prognostication of patients with AML if borne out repeatedly in large prospective trials of AML patients.